Abiomed, Inc. (ABMD) — Financial statements
Income statement, balance sheet, and cash flow for Abiomed, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,032↑21.7% | 848↑0.8% | 841↑9.3% | 769↑29.6% | 594 | |
| Cost of Revenue | 188↑16.2% | 162↑7.0% | 151↑16.8% | 130↑31.4% | 99 | |
| Gross Profit | 844↑23.0% | 686↓0.6% | 690↑7.8% | 640↑29.2% | 495 | |
| Operating Expenses | ||||||
| R&D Expenses | 163↑34.1% | 122↑23.4% | 99↑5.6% | 94↑24.2% | 75 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 322↑22.4% | 263 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 423↑26.7% | 334↓2.2% | 342↑6.2% | 322↑22.4% | 263 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.39 | |
| Operating Expenses | 587↑28.7% | 456↑3.6% | 440↑6.1% | 415↑22.8% | 338 | |
| Total Costs & Expenses | 775↑25.4% | 618↑4.4% | 592↑8.6% | 545↑24.7% | 437 | |
| Operating Results | ||||||
| Operating Income | 373↑62.4% | 230↓7.9% | 249↑10.9% | 225↑43.1% | 157 | |
| Depreciation & Amortization | 28↑16.6% | 24↑17.9% | 20↑44.7% | 14↑28.3% | 11 | |
| EBITDA | 500↑102.7% | 247↓4.1% | 257↑11.6% | 231↑40.3% | 164 | |
| EBIT | 472 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 50 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 50 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -100 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -182↓410.5% | 59↑671.3% | 8↓80.3% | 39↑1068.1% | 3 | |
| Income Before Tax | 191↓33.9% | 288↑12.2% | 257↓2.5% | 263↑64.2% | 160 | |
| Income Tax Expense | 54↓13.8% | 63↑16.5% | 54↑1138.9% | 4↓91.0% | 48 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 137↓39.5% | 226↑11.1% | 203↓21.6% | 259↑130.9% | 112 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 137↓39.5% | 226↑11.1% | 203↓21.6% | 259↑130.9% | 112 | |
| Bottom-Line Net Income | 137↓39.5% | 226↑11.1% | 203↓21.6% | 259↑130.9% | 112 | |
| EPS (Basic) | 3.00↓40.0% | 5.00↑11.4% | 4.49↓22.2% | 5.77↑127.2% | 2.54 | |
| EPS (Diluted) | 2.98↓39.7% | 4.94↑11.5% | 4.43↓21.0% | 5.61↑129.0% | 2.45 | |
| Weighted Average Shares | 45↑0.7% | 45↓0.1% | 45↑0.6% | 45↑1.7% | 44 | |
| Weighted Average Diluted Shares | 46↑0.5% | 46↓0.3% | 46↓0.7% | 46↑0.7% | 46 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.